Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada

BMC Infectious Diseases

Table 2 Indirect effects, immunogenicity, and indirect effect adjustments for PCV7, PCV10, and PCV13

	Bacteremia	Meningitis	Inpatient PNE	Outpatient PNE	Mild AOM	Moderate/Severe AOM	Source(s)/ Assumption
Indirect effects (years)
PCV7
0–2	0.68	0.68	0.07	0.16	0.21	0.15	[40, 42, 44, 65]
3–4	0.68	0.68	0.00	0.00	0.00	0.00
5–17	0.39	0.39	0.00	0.00	0.00	0.00
18–64	0.47	0.47	0.26	0.00	0.00	0.00
64+	0.36	0.36	0.00	0.00	0.00	0.00
PCV10 (for Sensitivity analysis)^a,b
0–2	0.41	0.41	0.04	0.10	0.13	0.09
3–4	0.43	0.43	0.00	0.00	0.00	0.00
5–17	0.26	0.26	0.00	0.00	0.00	0.00
18–64	0.39	0.39	0.22	0.00	0.00	0.00
64+	0.28	0.28	0.00	0.00	0.00	0.00
PCV13¹
0–2	0.59	0.59	0.06	0.14	0.18	0.13
3–4	0.62	0.62	0.00	0.00	0.00	0.00
5–17	0.30	0.30	0.00	0.00	0.00	0.00
18–64	0.55	0.55	0.30	0.00	0.00	0.00
64+	0.42	0.42	0.00	0.00	0.00	0.00
Immuno-genicity for PCV10 Direct Effects	0.90	0.90	0.85	0.80	0.75	0.75	[36]

AOM acute otitis media; PCV7 7-valent pneumococcal polysaccharide-protein conjugate vaccine; PCV10 10-valent pneumococcal conjugate vaccine; PCV13 13-valent pneumococcal conjugate vaccine; PNE pneumonia.
^a Adjusted for serotype coverage and year of coverage.
^b Indirect effects for PCV10 are assumed to be 0 in the base case.

ISSN: 1471-2334